CHIKUNGUNYA VIRUS E2 ENVELOPE PROTEIN (E.coli)
Chikungunya Virus E2 Envelope Protein (E.coli) has been manufactured in response to the need for high purity recombinant Chikungunya antigens for immunoassays. This protein is produced in E. coli cells and has greater than 95% purity. Major application of this antigen is detection of Chikungunya virus specific IgG/IgM by rapid test device.
PRODUCT DETAILS – CHIKUNGUNYA VIRUS E2 (E.coli)
- Chikungunya Virus E2 Envelope Protein
- Recombinant E2 protein expressed in E.coli.
- Greater than 95% purity.
- Major application of this antigen is detection of Chikungunya virus specific IgG/IgM by rapid test device.
Chikungunya fever is a debilitating arthritic disease caused by chikungunya virus (CHIKV). CHIKV was first identified in 1952–53 during an outbreak in southern Tanzania. It is a small (~70 nm in diameter), enveloped virus that is a member of the Old-World Semliki Forest virus group of arthritogenic alphaviruses within the Togaviridae family. CHIKV infection is commonly characterised by acute fever that progresses to severe, persistent arthralgia in the chronic stage of disease. The disease is usually self-limiting, but in some patients debilitating joint pain can persist for years. Dengue virus has been reported to infect the same cell types as CHIKV. Historically, CHIKV has been endemic in tropical and subtropical regions of sub-Saharan Africa and Southeast Asia, where two distinct CHIKV transmission cycles exist; a rural enzootic transmission cycle, which occurs between various forest or savannah Aedes spp. mosquitoes and animal reservoirs. However, during urban epidemics, CHIKV can also be transmitted to human hosts by Aedes spp. mosquitoes.
Chikungunya virus has ~12 kb positive-sense RNA genome that encodes four non-structural proteins (nsP1–4), with five structural proteins (C, E3, E2, 6K, and E1). The genome is packed into virions that are similar to those of other alphaviruses and embedded within the viral envelope are heterodimers of the E1 and E2 glycoproteins arranged in trimers forming an icosahedral lattice. E1 mediates fusion of the viral envelope and cellular membrane via a fusion peptide. The E2 envelope protein is a type I transmembrane glycoprotein which mediates binding to receptors and attachment factors on cell membrane; major target of neutralizing antibodies (reviewed in Silva and Dermody, 2017).
Bacterially produced subunit vaccines based on recombinant E2 and E1 protein antigens, delivered in combination with different adjuvants, have been shown to induce the production of high amounts of neutralising antibodies (reviewed in Burt et al., 2017). Mammalian produced virus-like particles (VLPs) have also shown promise as vaccine candidates.
- Burt et al. (2017). Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017 Apr;17(4):e107-e117.
- Silva and Dermody (2017). Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 127(3): 737–749.